Major trial launches for new scleroderma pill aiming to slow the Hard-to-Treat disease

This large, late-stage study is testing whether a new oral medication called nerandomilast can help control systemic sclerosis (scleroderma), a rare autoimmune disease that causes skin thickening and can damage internal organs. About 448 adults with early-stage scleroderma will be randomly assigned to take either the real drug or a placebo pill twice daily for 1 to 4 years. Researchers will closely monitor changes in skin thickness, lung function, and overall health to see if the treatment safely slows disease progression and improves patients' daily lives.